Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells

Biochemical and Biophysical Research Communications

Volumn 401, Issue 2, 2010, Pages 231-237

  Liu, Ying ^a,b,c   Huo, Zhaoxia ^a,b,c   Yan, Biao ^a,b,c   Lin, Xiaoping ^a,c   Zhou, Zhao Nian ^d   Liang, Xingqun ^e   Zhu, Weidong ^a,b   Liang, Dandan ^a,b   Li, Li ^a,b   Liu, Yi ^a,b   Zhao, Hong ^b   Sun, Yunfu ^a,b   Chen, Yi Han ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d Chinese Academy of Sciences   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Bcl 2; Cardiomyocytes; Prolyl hydroxylases

Indexed keywords

CASPASE 3; CASPASE 7; DOXORUBICIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE; DOXORUBICIN; HUMANS; MYOCYTES, CARDIAC; PROCOLLAGEN-PROLINE DIOXYGENASE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS;

MAMMALIA; RATTUS;

EID: 77957804993     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.037     Document Type: Article

References (39)

1. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
2. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell 1997, 88:347-354.
3. Reed J.C. Mechanisms of apoptosis. Am. J. Pathol. 2000, 157:1415-1430.
4. Wencker D., Chandra M., Nguyen K., Miao W., Garantziotis S., Factor S.M., Shirani J., Armstrong R.C., Kitsis R.N. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 2003, 111:1497-1504.
5. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
6. Epstein A.C., Gleadle J.M., McNeil L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
7. Kaelin W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 2005, 74:115-128.
8. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin W.G., Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005, 8:155-167.
9. Narula J., Pandey P., Arbustini E., Haider N., Narula N., Kolodgie F.D., Bello B.D., Semigran M.J., Bielsa-Masdeu A., Dec G.W., Israels S., Ballester M., Virmani R., Saxena S., Kharbanda S. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 1999, 96:8144-8149.
10. Saraste K., Pulkki K., Kallajoki M., Henriksen K., Parvinen M., Voipio-Pulkki L.M. Apoptosis in human acute myocardial infarction. Circulation 1997, 95:320-323.
11. Narula J., Haider N., Virmani R., DiSalvo T.G., Kolodgie F.D., Hajjar R.J., Schmidt U., Semigran M.J., Dec G.W., Khaw B.A. Apoptosis in myocytes in end-stage heart failure. N. Engl. J. Med. 1996, 335:1182-1189.
12. Ekhterae D., Lin Z., Lundberg M.S., Crow M.T., Brosius F.C., Núñez G. ARC inhibits cytochrome c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ. Res. 1999, 85:e70-e77.
13. Frias M.A., Somers S., Gerber-Wicht C., Opie L.H., Lecour S., Lang U. The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis. Cardiovasc. Res. 2008, 80:69-77.
14. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., Steele G.D., Chen L.B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA 1991, 88:3671-3675.
15. Zamzami N., Marchetti P., Castedo M., Zanin C., Vayssiere J.L., Petit P.X., Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 1995, 181:1661-1672.
16. Huang D.C., Adams J.M., Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998, 17:1029-1039.
17. Hanada M., Aime-Sempe C., Sato T., Reed J.C. Structure-function analysis of Bcl-2 protein: identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J. Biol. Chem. 1995, 270:11962-11969.
18. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
19. Heath-Engel H.M., Shore G.C. Regulated targeting of Bax and Bak to intracellular membranes during apoptosis. Cell Death Differ. 2006, 13:1277-1280.
20. Hsu Y.T., Youle R.J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J. Biol. Chem. 1998, 273:10777-10783.
21. Lieb M.E., Menzies K., Moschella M.C., Ni R., Taubman M.B. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem. Cell Biol. 2002, 80:421-426.
22. Takeda K., Ho V.C., Takeda H., Duan L.J., Nagy A., Fong G.H. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 2006, 26:8336-8346.
23. Percy M.J., Zhao Q., Flores A., Harrison C., Lappin T.R., Maxwell P.H., McMullin M.F., Lee F.S. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl. Acad. Sci. USA 2006, 103:654-659.
24. Wax S.D., Tsao L., Lieb M.E., Fallon J.T., Taubman M.B. SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle. Lab. Invest. 1996, 74:797-808.
25. Rohrbach S., Simm A., Pregla R., Franke C., Katschinski D.M. Age-dependent increase of prolyl-4-hydroxylase domain (PHD) 3 expression in human and mouse heart. Biogerontology 2005, 6:165-171.
26. Willam C., Maxwell P.H., Nichols L., Lygate C., Tian Y., Bernhardt W., Wiesener M., Ratcliffe P.J., Eckardt K., Pugh C.W. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J. Mol. Cell. Cardiol. 2006, 41:68-77.
27. Zolk O., Solbach T.F., Eschenhagen T., Weidemann A., Fromm M.F. Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure. Biochem. Biophys. Res. Commun. 2008, 376:315-320.
28. Bishop T., Gallagher D., Pascual A., Lygate C.A., de Bono J.P., Nicholls L.G., Ortega-Saenz P., Oster H., Wijeyekoon B., Sutherland A.I., Grosfeld A., Aragones J., Schneider M., Geyte K., Teixeira D., Diez-Juan A., Lopez-Barneo J., Channon K.M., Maxwell P.H., Pugh C.W., Davies A.M., Carmeliet P., Ratcliffe P.J. Abnormal sympathoadrenal development and systemic hypotension in PHD3_/_ mice. Mol. Cell. Biol. 2008, 28:3386-3400.
29. Adams J.M., Cory S. The Bcl-2-regulated apoptosis switch: mechanism and therapeutic potential. Curr. Opin. Immunol. 2007, 19:488-496.
30. Kenis Y., Michel J., Rimoldi R., Levy P., Israel L. Results of a clinical trial with intermittent doses of adriamycin in lung cancer. Eur. J. Cancer 1972, 8:485-489.
31. Minow R.A., Benjamin R.S., Gottlieb J.A. Adriamycin (NSC123127) cardiomyopathy-an overview with determination of risk factors. Cancer Chemother. Rep. 1975, 6:198-201.
32. Kotamraju S., Konorev E.A., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 2000, 275:33585-33592.
33. Fisher P.W., Salloum F., Das A., Hyder H., Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiomyopathy. Circulation 2005, 111:1601-1610.
34. Sawyer D.B., Fukazawa R., Arstall M.A., Kelly R.A. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 1999, 84:257-265.
35. Gamen S., Anel A., Perez-Galan P., Lasierra P., Johnson D., Pineiro A., Naval J. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes ΔΨm loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp. Cell Res. 2000, 258:223-235.
36. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 2002, 234/235:119-124.
37. Eom Y.W., Kim M.A., Park S.S., Goo M.J., Kwon H.J., Sohn S., Kim W.H., Yoon G., Choi K.S. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005, 24:4765-4777.
38. Ueno M., Kakinuma Y., Yuhki K., Murakoshi N., Iemitsu M., Miyauchi T., Yamaguchi I. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J. Pharmacol. Sci. 2006, 101:151-158.
39. Kim D.S., Woo E.R., Chae S.W., Ha K.C., Lee G.H., Hong S.T., Kwon D.Y., Kim M.S., Jung Y.K., Kim H.M., Kim H.K., Kim H.R., Chae H.J. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation. Life Sci. 2007, 80:314-323.